PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background We conducted a systematic review and meta-analysis to dissect the association between PIK3CA mutations and resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) according to PIK3CA exon of mutations in metastatic colorectal cancer (mCRC).Methods We systematically identified studies exploring the association between PIK3CA mutations and clinical outcomes of mCRC patients treated with anti-EGFR MoAbs. The primary clinical outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). The pooled relative risk (RR) or hazard ratio (HR) was estimated by using fixed effect model or random effect model according to heterogeneity between studies.Results Thirteen studies were considered eligible, with 576 mCRC patients included. In KRAS wild-type mCRC patients, we observed a lower ORR in patients with PIK3CA exon 20 mutations [3 studies, 377 patients; ORR = 0% versus 37%; RR = 0.25; 95% confidence interval (CI) 0.05-1.19; P = 0.082], although the result was not statistically significant because of the small sample size. Only one study provided survival data according to the PIK3CA exon of the mutations, in which PIK3CA exon 20 mutations were statistically significantly associated with shorter PFS (HR = 2.52; 95% CI 1.33-4.78; P = 0.013) and OS (HR = 3.29; 95% CI 1.60-6.74; P = 0.006) in KRAS wild-type mCRC patients treated with anti-EGFR MoAbs. The predictive power of exon 20 mutation is greater than exon 9 mutations and all exons mutations in terms of ORR, PFS, and OS.Conclusion These analyses suggest that PIK3CA exon 20 mutations may be a potential biomarker for resistance to anti-EGFR MoAbs in KRAS wild-type mCRC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, PIK3CA exon 20 mutations significantly reduced the anti-EGFR response rate in the case of KRAS-WT, while exon 9 mutations had no significant effect [167,168].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [168]
In the citing paper
“The most common mutations in PIK3CA are in exons 9 (68.5%) and 20 (20.4%), and they are detected in 10–18% of mCRC [11, 105].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [105]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 1×
“10) was found and cannot be explained [27].”
BackgroundThe combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380 · cited 1×
“Heterogeneity was assessed by the Q-test with a df equal to the number of included studies minus one [26].”
MethodCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“Recently, two monoclonal antibodies (MoAbs) targeted at epidermal growth factor receptor (EGFR), the chimeric immunoglobulin G1 MoAb cetuximab and the fully humanized immunoglobulin G2 panitumumab, were found effective in combination with chemotherapy or as single therapeutic agent for chemotherapy-resistant mCRC [2,…”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Modern Epidemiology 3rd edition
Rothman, K. J., Lash, T. L., & Greenland, S. (1986) · Cited by 3,098
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 22×
“Five studies for KRAS wild-type patients all reported a shorter median PFS [21, 23] or OS [21, 23, 24] in PIK3CA mutant patients than in PIK3CA wild patients, although none of the results was statistically significant.”
BackgroundMethodResultInfluentialRothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9807 · Cited by 360
Duffy, M. J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., & Sturgeon, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.28384 · Cited by 360
Brulé, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R., Tebbutt, N. C., Underhill, C., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 332
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
“Subsequently, the conclusion drawn from a metaanalysis of 13 retrospective cohort studies was that only PIK3CA exon 20 mutations were associated with a lack of response to anti-EGFR MoAbs [62].”
BackgroundGenetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer
Coppedè, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.943 · Cited by 264
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
The Role of EREG/EGFR Pathway in Tumor Progression
Cheng, W.-L., Feng, P.-H., Lee, K.-Y., Chen, K.-Y., Sun, W.-L., Van Hiep, N., Luo, C.-S., & Wu, S.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312828 · Cited by 239
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Massacesi, C., Di Tomaso, E., Urban, P., Germa, C., Quadt, C., Trandafir, L., Aimone, P., Fretault, N., Dharan, B., Tavorath, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s89967 · Cited by 229
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
Afrăsânie, V.-A., Marinca, M. V., Alexa-Stratulat, T., Gafton, B., Păduraru, M., Adavidoaiei, A. M., Miron, L., & Rusu, C. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0033 · Cited by 159
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis
Mei, Z., Duan, C., Li, C. B., Cui, L., & Ogino, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw264 · Cited by 165
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.001 · Cited by 157
Rosty, C., Young, J. P., Walsh, M. D., Clendenning, M., Sanderson, K., Walters, R. J., Parry, S., Jenkins, M. A., Win, A. K., Southey, M. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065479 · Cited by 145
Molecular phenotypes of colorectal cancer and potential clinical applications
Kocarnik, J. M., Shiovitz, S., & Phipps, A. I. (2015) · Gastroenterology Report · doi:10.1093/gastro/gov046 · Cited by 132
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Day, F. L., Jorissen, R. N., Lipton, L., Mouradov, D., Sakthianandeswaren, A., Christie, M., Li, S., Tsui, C., Tie, J., Desai, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3614 · Cited by 124
Zhang, J., Zheng, J., Yang, Y., Lu, J., Gao, J., Lu, T., Sun, J. H., Jiang, H., Zhu, Y., Zheng, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep18678 · Cited by 139
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Biomarker concordance between primary colorectal cancer and its metastases
Bhullar, D. S., Barriuso, J., Mullamitha, S., Saunders, M. P., O'Dwyer, S. T., & Aziz, O. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.050 · Cited by 115
Important molecular genetic markers of colorectal cancer
Kudryavtseva, A. V., Lipatova, A. V., Zaretsky, A. R., Moskalev, A. A., Fedorova, M. S., Rasskazova, A. S., Shibukhova, G. A., Snezhkina, A. V., Kaprin, A. D., Alekseev, B. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9796 · Cited by 114
Zhai, Z., Yu, X., Yang, B. J., Zhang, Y., Zhang, L., Li, X., & Sun, H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.033 · Cited by 120
Shen, Y., Wang, J., Han, X., Yang, H., Wang, S., Lin, D., & Shi, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081628 · Cited by 100
Pietrantonio, F., Cremolini, C., Petrelli, F., Bartolomeo, M. D., Loupakis, F., Maggi, C., Antoniotti, C., de Braud, F., Falcone, A., & Iacovelli, R. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.016 · Cited by 99
AKT-independent PI3-K signaling in cancer – emerging role for SGK3
Hannan, R., Bruhn, Pearson, R., & Sheppard (2013) · Cancer Management and Research · doi:10.2147/cmar.s35178 · Cited by 83
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 115
ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development
Fang, L., Lu, W., Choi, H. H., Yeung, S.-C. J., Tung, J.-Y., Hsiao, C.-D., Fuentes-Mattei, E., Menter, D., Chen, C., Wang, L., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.004 · Cited by 80
The emerging role of PI3K inhibitors for solid tumour treatment and beyond
Belli, C., Repetto, M., Anand, S. K., Porta, C., Subbiah, V., & Curigliano, G. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02221-1 · Cited by 82
Al-Shamsi, H. O., Jones, J. C., Fahmawi, Y., Dahbour, I., Tabash, A., Abdel‐Wahab, R., Abousamra, A., Shaw, K. R. M., Xiao, L., Hassan, M. M., et al. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.02 · Cited by 94
Fang, W., Huang, K., Lan, Y., Lin, C., Chang, S., Chen, M., Chao, Y., Lin, W., Lo, S.-S., Li, A. F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6641 · Cited by 81
Mao, C., Zhou, J., Yang, Z., Huang, Y., Wu, X., Shen, H., Tang, J., & Chen, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036653 · Cited by 75
Self-citationGinghină, O., Hudiță, A., Zamfir, M., Spânu, A., Mardare, M., Bondoc, I., Buburuzan, L., Georgescu, S. E., Costache, M., Negrei, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856575 · Cited by 80
Methods of overcoming treatment resistance in colorectal cancer
Temraz, S. N., Mukherji, D., Alameddine, R. S., & Shamseddine, A. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.015 · Cited by 75
Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach
Blanco, M., Concha, Á., Figueroa, A., Garrido, F., & Valladares‐Ayerbes, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613610 · Cited by 72
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer
Dirican, E., Akkіprіk, M., & Özer, A. (2016) · Tumor Biology · doi:10.1007/s13277-016-4924-2 · Cited by 65
Chen, S., Liu, H., Liao, C., Huang, P.-J., Huang, Y., Hsu, A., Tang, P., Chang, Y., Chen, H., & Yen, T. (2015) · Oncotarget · doi:10.18632/oncotarget.3768 · Cited by 67
Takahashi, N., Yamada, Y., Furuta, K., Honma, Y., Iwasa, S., Takashima, A., Kato, K., Hamaguchi, T., & Shimada, Y. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.230 · Cited by 66
Jesinghaus, M., Konukiewitz, B., Foersch, S., Stenzinger, A., Steiger, K., Muckenhuber, A., Groß, C., Mollenhauer, M., Roth, W., Detlefsen, S., et al. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.184 · Cited by 61
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw209 · Cited by 69
Lai, K., Killingsworth, M. C., & Lee, C. S. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202885 · Cited by 74
Markers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib, W. L., Mahajan, R., & El‐Rayes, B. F. (2013) · PubMed · doi:10.3978/j.issn.2078-6891.2013.029 · Cited by 53
Nam, S. K., Yun, S., Koh, J., Kwak, Y., Seo, A. N., Park, K. U., Kim, D.-W., Kang, S.-B., Kim, W. H., & Lee, H. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151865 · Cited by 56
Haley, L. M., Tseng, L., Zheng, G., Dudley, J. C., Anderson, D. A., Azad, N. S., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.86 · Cited by 60
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 66
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients
Yanus, G. A., Belyaeva, A. V., Ivantsov, A. O., Kuligina, E. S., Suspitsin, E. N., Mitiushkina, N. V., Алексахина, С. Н., Iyevleva, A. G., Zaitseva, O. A., Yatsuk, O. S., et al. (2013) · Medical Oncology · doi:10.1007/s12032-013-0686-5 · Cited by 58
Takahashi, N., Yamada, Y., Taniguchi, H., Fukahori, M., Sasaki, Y., Shoji, H., Honma, Y., Iwasa, S., Takashima, A., Kato, K., et al. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-271 · Cited by 54
Current and Emerging Biomarkers in Metastatic Colorectal Cancer
Lee, M. K. C., & Loree, J. M. (2019) · Current Oncology · doi:10.3747/co.26.5719 · Cited by 52
Sanaei, M., Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Shahrokh, S., Zali, M. R., & Bashash, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30655 · Cited by 63
Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial
Ogino, S., Liao, X., Imamura, Y., Yamauchi, M., McCleary, N. J., Ng, K., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Whittom, R., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt298 · Cited by 49
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Luo, H., & Xu, R.-H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3858 · Cited by 56
Boeckx, N., Janssens, K., Camp, G. V., Rasschaert, M. A., Papadimitriou, K., Peeters, M., & de Beeck, K. O. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.003 · Cited by 50
Jin, J., Shi, Y., Zhang, S., & Yang, S. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1664764 · Cited by 47
Guinney, J., Ferté, C., Dry, J., McEwen, R., Manceau, G., Kao, K., Chang, K.-M., Bendtsen, C., Hudson, K., Huang, E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1943 · Cited by 43
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 51
Bowles, D. W., Kochenderfer, M., Cohn, A., Sideris, L., Nguyen, N., Cline-Burkhardt, V., Schnadig, I., Choi, M., Nabell, L., Chaudhry, A., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.03.004 · Cited by 42
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer
Cai, Y., Yousef, A., Grandis, J. R., & Johnson, D. E. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100653 · Cited by 51
Wu, S., Gan, Y., Wang, X., Liu, J., Li, M., & Tang, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1400-x · Cited by 50
Maeng, C. H., Lee, J., Hummelen, P. V., Park, S. H., Palescandolo, E., Jang, J., Park, H. Y., Kang, S. Y., MacConaill, L. E., Kim, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041655 · Cited by 43
Yang, Z.-Y., Shen, W.-X., Hu, X.-F., Zheng, D.-Y., Wu, X.-Y., Huang, Y.-F., Chen, J.-Z., Mao, C., & Tang, J.-L. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-52 · Cited by 40
Self-citationSomatic gene mutations in African Americans may predict worse outcomes in colorectal cancer
Kang, M. S., Shen, X., Kim, S., Araújo-Pérez, F., Galanko, J. A., Martin, C. F., Sandler, R. S., & Keku, T. O. (2013) · Cancer Biomarkers · doi:10.3233/cbm-130366 · Cited by 44
Proteins are potent biomarkers to detect colon cancer progression
Kuppusamy, P., Govindan, N., Yusoff, M. M., & Ichwan, S. J. A. (2014) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2014.09.017 · Cited by 43
Palomba, G., Colombino, M., Contu, A. S., Massidda, B., Baldino, G., Pazzola, A., Ionta, M. T., Capelli, F., Trova, V., Sedda, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-178 · Cited by 40
Luo, Q., Chen, D., Fan, X., Fu, X., Ma, T., & Chen, D. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100874 · Cited by 42
Bisht, S., Ahmad, F., Sawaimoon, S. K., Bhatia, S., & Das, B. R. (2014) · Medical Oncology · doi:10.1007/s12032-014-0124-3 · Cited by 40
Loree, J. M., Kopetz, S., & Raghav, K. P. S. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.01 · Cited by 38
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Lai, E., Liscia, N., Donisi, C., Mariani, S., Tolu, S., Pretta, A., Persano, M., Pinna, G., Balconi, F., Pireddu, A., et al. (2020) · Cancers · doi:10.3390/cancers12051214 · Cited by 41
Ciepiela, I., Szczepaniak, M., Ciepiela, P., Hińcza, K., Kopczyński, J., Macek, P., Kubicka, K., Chrapek, M., Tyka, M., Góźdź, S. S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55139-w · Cited by 59
Jesinghaus, M., Pfarr, N., Endris, V., Kloor, M., Volckmar, A., Brandt, R., Herpel, E., Muckenhuber, A., Lasitschka, F., Schirmacher, P., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22352 · Cited by 38
Huang, L., Liu, Z., Deng, D., Tan, A., Liao, M., Mo, Z., & Yang, X. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.40728 · Cited by 39
Somatic Mutations of K-Ras and BRAF in Thai Colorectal Cancer and their Prognostic Value
Chaiyapan, W., Duangpakdee, P., Boonpipattanapong, T., Kanngern, S., & Sangkhathat, S. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.1.329 · Cited by 33
Ålgars, A., Sundström, J. T. T., Lintunen, M., Jokilehto, T., Kytölä, S. I., Kaare, M., Vainionpää, R., Orpana, A., Osterlund, P. J., Ristimaki, A. P., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30507 · Cited by 37
Binding Selectivity Studies of Phosphoinositide 3-Kinases Using Free Energy Calculations
Sabbah, D. A., Vennerstrom, J. L., & Zhong, H. A. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3003057 · Cited by 37
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 35
Bartolomeo, M. D., Pietrantonio, F., Perrone, F., Dotti, K. F., Lampis, A., Bertan, C. M., Beretta, E., Rimassa, L., Carbone, C., Biondani, P., et al. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0283-8 · Cited by 36
Zhou, X., Liang, M., Shi, B., Liu, J., Gao, Y., Zhou, L., He, L., & Yu, G. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85525 · Cited by 32
RetractedLeGolvan, M. P., Taliano, R., & Resnick, M. B. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.03.003 · Cited by 38
Połom, K., Marrelli, D., Roviello, G., Pascale, V., Voglino, C., Vindigni, C., Generali, D., & Roviello, F. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/70795 · Cited by 31
Qu, X., Hamidi, H., Johnson, R. M., Sokol, E. S., Lin, E., Eng, C., Kim, T.-W., Bendell, J. C., Sivakumar, S., Kaplan, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59588-3 · Cited by 38
Tural, D. G., Batur, Ş., Erdamar, S., Akar, E., Kepil, N., Mandel, N. M., & Serdengeçti, S. (2013) · Tumor Biology · doi:10.1007/s13277-013-1138-8 · Cited by 28
Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Martins, M., Mansinho, A., Cruz-Duarte, R., Lobo-Martins, S., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_8 · Cited by 30
Pang, S.-W., Awi, N. J., Armon, S., Lim, W. W.-D., Low, J. S.-H., Peh, K.-B., Peh, S., & Teow, S. (2019) · Diagnostics · doi:10.3390/diagnostics10010009 · Cited by 29
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
Bignucolo, A., Mattia, E. D., Cecchin, E., Roncato, R., & Toffoli, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071522 · Cited by 29
Pietrantonio, F., Maggi, C., Bartolomeo, M. D., Facciorusso, M. G., Perrone, F., Testi, M., Iacovelli, R., Miceli, R., Bossi, I. E., Leone, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092147 · Cited by 26
Sasaki, Y., Hamaguchi, T., Yamada, Y., Takahashi, N., Shoji, H., Honma, Y., Iwasa, S., Okita, N. T., Takashima, A., Kato, K., et al. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.539 · Cited by 27
Novel biotechnology approaches in colorectal cancer diagnosis and therapy
Kavousipour, S., Khademi, F., Zamani, M., Vakili, B., & Mokarram, P. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2303-8 · Cited by 26
Goel, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s162967 · Cited by 27
Genetic alterations shaping tumor response to anti-EGFR therapies
Vaquero, J., Pavy, A., Gonzalez‐Sanchez, E., Meredith, M., Arbelaiz, A., & Fouassier, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100863 · Cited by 26
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11600-z · Cited by 33
the DeCoDe PET group, Goos, J. A. C. M., Hiemstra, A. C., Coupé, V. M. H., Diosdado, B., Kooijman, W., Diemen, P. M. D., Karga, C., Beliën, J. A. M., van Oordt, C. W. M. D. H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.354 · Cited by 25
Alfonso, P. G., Salazar, R., García‐Foncillas, J., Musulén, E., García‐Carbonero, R., Payá, A., Pérez‐Segura, P., y Cajal, S. R., & Navarro, S. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0856-5 · Cited by 28
PIK3CAandTP53mutations predict overall survival of stage II/III colorectal cancer patients
Li, A., Li, H., Tang, E., Wu, W., Chen, Y., Jiang, H., Lin, M., & Yin, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i5.631 · Cited by 31
Goodwin, R. A., Jonker, D. J., Chen, E. X., Kennecke, H. F., Cabanero, M., Tsao, M., Vickers, M. M., Bohemier, C., Lim, H. J., Ritter, H. D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00814-3 · Cited by 27
Beyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Perkins, G., Pilati, C., Blons, H., & Laurent-Puig, P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.66 · Cited by 22
KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers
Yokoyama, M., Ohnishi, H., Ohtsuka, K., Matsushima, S., Ohkura, Y., Furuse, J., Watanabe, T., Mori, T., & Sugiyama, M. (2016) · Japanese Clinical Medicine · doi:10.4137/jcm.s40549 · Cited by 24
Kim, S. T., Lee, S.-J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., & Park, Y. S. (2017) · Journal of Cancer · doi:10.7150/jca.18286 · Cited by 24
Ma, C., Huang, C., Chang, T., Tsai, H., Su, W., Yeh, Y., Chen, P.-J., & Wang, J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.12.003 · Cited by 22
Metadata
- Authors
- Mao, C., Yang, Z. Y., Hu, X. F., Chen, Q., & Tang, J. L.
- Affiliations
- Chinese University of Hong Kong (HK)
- Southern Medical University (CN)
- Corresponding author
- Tang, J.L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 23
- Issue
- 6
- Pages
- 1518-1525
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2108455517
- Cited by
- 188
- References
- 38
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 10 · 2023: 12 · 2022: 10 · 2021: 5 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 11 · 2016: 24 · 2015: 17 · 2014: 25 · 2013: 20 · 2012: 10
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2730 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Health and Health Services Research Fund (HHSRF 09100561)
- from Food and Health Bureau of Hong Kong
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- anti-EGFR monoclonal antibody, KRAS wild-type, metastatic colorectal cancer, drug resistance, predictive biomarkers, objective response rate, progression-free survival, overall survival
- MeSH terms
- Cetuximab, Panitumumab, Antibodies, Monoclonal, Antineoplastic Agents, Exons, Humans, Mutation, Neoplasm Metastasis, Proto-Oncogene Proteins, Retrospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Genetic Association Studies, Class I Phosphatidylinositol 3-Kinases, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.